- Home
- TMQ vs CUE Comparison
TMQ vs CUE Comparison
Compare TMQ & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TMQ
- CUE
- Stock Information
- Founded
- TMQ 2004
- CUE 2014
- Country
- TMQ Canada
- CUE United States
- Employees
- TMQ N/A
- CUE N/A
- Industry
- TMQ Precious Metals
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- TMQ Basic Materials
- CUE Health Care
- Exchange
- TMQ Nasdaq
- CUE Nasdaq
- Market Cap
- TMQ 83.6M
- CUE 94.4M
- IPO Year
- TMQ N/A
- CUE 2018
- Fundamental
- Price
- TMQ $1.54
- CUE $1.32
- Analyst Decision
- TMQ
- CUE Strong Buy
- Analyst Count
- TMQ 0
- CUE 5
- Target Price
- TMQ N/A
- CUE $5.00
- AVG Volume (30 Days)
- TMQ 710.2K
- CUE 195.8K
- Earning Date
- TMQ 02-14-2025
- CUE 03-10-2025
- Dividend Yield
- TMQ N/A
- CUE N/A
- EPS Growth
- TMQ N/A
- CUE N/A
- EPS
- TMQ N/A
- CUE N/A
- Revenue
- TMQ N/A
- CUE $9,532,000.00
- Revenue This Year
- TMQ N/A
- CUE $73.11
- Revenue Next Year
- TMQ N/A
- CUE $11.02
- P/E Ratio
- TMQ N/A
- CUE N/A
- Revenue Growth
- TMQ N/A
- CUE 149.53
- 52 Week Low
- TMQ $0.25
- CUE $0.45
- 52 Week High
- TMQ $1.76
- CUE $2.37
- Technical
- Relative Strength Index (RSI)
- TMQ 69.98
- CUE 48.32
- Support Level
- TMQ $1.26
- CUE $1.22
- Resistance Level
- TMQ $1.46
- CUE $1.54
- Average True Range (ATR)
- TMQ 0.10
- CUE 0.11
- MACD
- TMQ 0.02
- CUE -0.01
- Stochastic Oscillator
- TMQ 59.26
- CUE 35.29
About TMQ Trilogy Metals Inc.
Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the United States. Its properties include the Arctic copper-zinc-lead-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.